Provided by Tiger Trade Technology Pte. Ltd.

N2OFF, Inc

1.02
-0.0500-4.67%
Post-market: 1.020.00000.00%16:51 EST
Volume:47.98K
Turnover:49.55K
Market Cap:2.83M
PE:-0.03
High:1.08
Open:1.05
Low:1.01
Close:1.07
52wk High:41.65
52wk Low:0.8756
Shares:2.77M
Float Shares:1.48M
Volume Ratio:0.42
T/O Rate:3.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-38.2406
EPS(LYR):-31.0892
ROE:-101.61%
ROA:-44.78%
PB:0.32
PE(LYR):-0.03

Loading ...

N2OFF highlights research on mitochondrial carriers in spaceflight conditions

TIPRANKS
·
Feb 02

MitoCareX Bio Advances Mitochondrial Drug Research Under N2OFF Inc

Reuters
·
Feb 02

In Spaceflight Conditions: N2OFF‘s MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions

GlobeNewswire
·
Feb 02

N2OFF: MitoCareX Bio Announces Positive In Vitro Results from Its Mitochondrial Carrier Small Molecule Platform

GlobeNewswire
·
Jan 22

MitoCareX Bio Advances Mitochondrial Drug Discovery Under N2OFF Inc

Reuters
·
Jan 15

N2OFF: MitoCareX Bio Spotlights Co-Founder's Pioneering Research on Mitochondrial Carriers in Spaceflight Stress Conditions

GlobeNewswire
·
Jan 15

N2off Inc. Announces Unregistered Sale of Shares Under Regulation S

Reuters
·
Jan 14

N2off Inc. Issues 35,000 Shares for Investor Relations Services

Reuters
·
Jan 12

N2OFF Invests $340,000 to Boost Profit Stake in German Solar Project

Reuters
·
Jan 05

N2OFF Advances German and Italian Renewable Projects with Key Regulatory Submissions

Reuters
·
Dec 29, 2025

N2OFF Accelerates European Renewable Energy Momentum with Major De-Risking Milestones and Approximately $1.69 Million Value Unlock in Germany and Italy

GlobeNewswire
·
Dec 29, 2025

N2off Inc. Held Annual Shareholder Meeting

Reuters
·
Dec 17, 2025

N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination

GlobeNewswire
·
Nov 18, 2025

N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers

GlobeNewswire
·
Oct 30, 2025

N2off Inc. Files Initial Statement of Beneficial Ownership; Dr. Alon Silberman Reported as 10% Owner

Reuters
·
Oct 29, 2025

N2off Inc. Discloses SciSparc Ltd. as 10% Owner in Initial Beneficial Ownership Filing

Reuters
·
Oct 25, 2025

N2OFF Inc. Announces Date for Upcoming Annual Stockholders Meeting

Reuters
·
Oct 24, 2025

SciSparc Closes Sale of MitoCareX to N2OFF

Reuters
·
Oct 24, 2025

Scisparc Announces Closing of the Sale to N2off of Majority-Owned Subsidiary Mitocarex, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Oct 24, 2025

N2OFF Closes Merger with MitoCareX Bio

Reuters
·
Oct 24, 2025